The IPO outlook for the second half of 2024, or at least the first half of 2025, can only get better. Riskier assets have rebounded strongly, and the after-market performance of some recent IPOs has been stronger.
Healthcare and Biotech companies often go public early in their financing path, driven by high risk and potential for returns with less capital. Investors are expected to focus on biotech, life sciences, and medical sectors.
[
Collection
]
[
|
...
]